Article/Intelligence
GSAM Refinances Nemera’s Existing Bank Debt With Over €1B Debt Package
Reporting: Lucia Camblor, Maryna Irkliyenko
The direct lending unit of Goldman Sachs Asset Management, or GSAM, is providing a debt package of more than €1 billion, including an up to €800 million cov-lite unitranche plus a capital expenditure facility, to refinance France-based medical devices manufacturer Nemera’s existing bank debt, sources told Octus, formerly Reorg.
The refinancing was structured off Nemera’s EBITDA of €138.3 million, the sources said.
The unitranche facility is priced at around 500 bps over the reference rate, the sources said. The financing includes a portability clause, the sources noted.
The incumbent sponsors Astorg and Montagu decided to refinance the business due to high capex spend that was likely to result in a downgrade by the credit ratings agencies, the sources said.
In June 2024, Nemera allocated a €625 million term loan B repriced at par with E+425 bps margin and a $75 million at par with S+450 bps, as reported. Physical bookrunners for the deal included HSBC and Natixis.
In April 2024, S&P global ratings affirmed the company’s B- ratings on the group’s senior secured debt facilities, including the proposed term loan B add-on. The recovery ratings of 3, with 55% recovery prospects, remained unchanged.
Octus’ ESG analysis of Nemera is HERE.
In 2018, Astorg acquired Nemera from Montagu Private Equity for €1.04 billion on a ppre-IFRS 16 basis at a 14.7x EV multiple based on a pro forma EBITDA of €71 million, according to Fundamentals by Octus.
In 2019, Montagu reinvested in Nemera alongside another investor to support the next phase of Nemera’s growth, according to the sponsors’ website.
Astorg and Montagu each own 45% stake in the business and the rest is owned by the company’s management.
According to Octus’ CLO database Nemera’s loans are held by the following managers. Click HERE to see the holders in the database.
Nemera has its headquarters near Lyon, France. The company is a global manufacturer of drug delivery devices, with a broad portfolio of devices such as insulin pens or dry powder inhalers.
GSAM and Montagu declined to comment. Astorg did not reply to Octus’ request for comment.
This publication has been prepared by Octus, Inc. or one of its affiliates (collectively, "Octus") and is being provided to the recipient in connection with a subscription to one or more Octus products. Recipient’s use of the Octus platform is subject to Octus Terms of Use or the user agreement pursuant to which the recipient has access to the platform (the “Applicable Terms”). The recipient of this publication may not redistribute or republish any portion of the information contained herein other than with Octus express written consent or in accordance with the Applicable Terms. The information in this publication is for general informational purposes only and should not be construed as legal, investment, accounting or other professional advice on any subject matter or as a substitute for such advice. The recipient of this publication must comply with all applicable laws, including laws regarding the purchase and sale of securities. Octus obtains information from a wide variety of sources, which it believes to be reliable, but Octus does not make any representation, warranty, or certification as to the materiality or public availability of the information in this publication or that such information is accurate, complete, comprehensive or fit for a particular purpose. Recipients must make their own decisions about investment strategies or securities mentioned in this publication. Octus and its officers, directors, partners and employees expressly disclaim all liability relating to or arising from actions taken or not taken based on any or all of the information contained in this publication. © 2025 Octus. All rights reserved. Octus(TM) and the Octus logo are trademarks of Octus Intelligence, Inc.